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Abstract
Background: Cyclooxygenase-2 (COX-2) contributes to ventilation induced lung injury (VILI) and acute respiratory
distress syndrome (ARDS). The objective of present study was to observe the therapeutic effect of parecoxib on VILI
in ARDS.
Methods: In this parallel controlled study performed at Harbin Medical University, China between January 2016 and
March 2016, 24 rats were randomly allocated into sham group (S), volume ventilation group/ARDS (VA), parecoxib/
volume ventilation group/ARDS (PVA). Rats in the S group only received anesthesia; rats in the VA and PVA group
received intravenous injection of endotoxin to induce ARDS, and then received ventilation. Rats in the VA and PVA
groups were treated with intravenous injection of saline or parecoxib. The ratio of arterial oxygen pressure to
fractional inspired oxygen (PaO2/FiO2), the wet to dry weight ratio of lung tissue, inflammatory factors in serum and
bronchoalveolar lavage fluid (BALF), and histopathologic analyses of lung tissue were examined. In addition, survival
was calculated at 24 h after VILI.
Results: Compared to the VA group, in the PVA group, PaO2/FiO2 was significantly increased; lung tissue wet to dry
weight ratio; macrophage and neutrophil counts, total protein and neutrophil elastase levels in BALF; tumor necrosis
factor-α, interleukin-1β, and prostaglandin E2 levels in BALF and serum; and myeloperoxidase (MPO) activity,
malondialdehyde levels, and Bax and COX-2 protein levels in lung tissue were significantly decreased, while
Bcl-2 protein levels were significantly increased. Lung histopathogical changes and apoptosis were reduced
by parecpxib in the PVA group. Survival was increased in the PVA group.
Conclusions: Parecoxib improves gas exchange and epithelial permeability, decreases edema, reduces local
and systemic inflammation, ameliorates lung injury and apoptosis, and increases survival in a rat model of VILI.
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Background
Mechanical ventilation (MV) is an essential therapy for
patients with severe lung injury or respiratory dysfunc-
tion. However, large volume and long-term ventilation
can cause ventilation induced lung injury (VILI) [1]. MV
with large tidal volume can result in regional overdis-
tention of alveoli and airways, and the release of pro-
inflammatory cytokines and prostanoids. This can
cause local inflammation and lung injury [2], as well
as systemic inflammation that can contribute to mul-
tiple organ failure and death.
Patients with acute respiratory distress syndrome
(ARDS) or prior lung injury usually require MV support
to guarantee oxygenation [3], and are particularly sus-
ceptible to VILI. Although lung protective strategies and
other therapies are used during MV in ARDS patients,
the therapeutic effect remains unsatisfactory [4–6].
Cyclooxygenase-2 (COX-2) plays an important role in
inflammation, and inhibition of COX-2 production can
attenuate local or systemic inflammation, including the
production of chemokines and pro-inflammatory cyto-
kines [7–9]. Evidence suggests that COX-2 inhibitors
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reduce pulmonary inflammation in animal models of lung
injury [10–13], COX-2 contributes to ARDS [14, 15] and
VILI [16], and inhibition of COX-2 reduces VILI [17] or
acute lung injury induced by pancreatitis [7]. However,
COX-2 inhibition or gene disruption is not currently ap-
plicable in the clinic. A previous report from our labora-
tory indicates that parecoxib, a COX-2–specific inhibitor
that has widespread clinical use, attenuates lung injury
induced by meconium in rabbits [13]. There are no
published studies investigating the long term effect of par-
ecoxib on VILI in ARDS. In the current study, we investi-
gated the effect of parecoxib on VILI in a rat model of
ARDS, considering short and long term outcomes. The




Twenty-four adult (275-375 g) male Wistar rats were
purchased from the Second Affiliated Hospital of Harbin
Medical University, Harbin, China. The present study
was approved by the Ethics Committee of Harbin
Medical University, China. All experiments were per-
formed in accordance with the guidelines of Institutional
Animal Care and Use Committee of Harbin Medical
University, China. Rats were fasted for 24 h before the
study, but water was provided ad libitum.
Rats were randomly allocated into: sham group (S),
large volume ventilation group/ARDS (VA), parecoxib/
large volume ventilation group/ARDS (PVA). All rats were
anesthetized with 3% pentobarbital sodium (30 mg/kg)
and rocuronium 0.6 mg/kg by intraperitoneal injection.
Rats in the VA and PVA groups were intubated and ad-
ministered an intravenous injection of endotoxin 500 μg/
kg (Escherichia coli endotoxin, 0111:B4, Sigma, Saint
Louis, Missouri, USA). Then, rats in the VA and PVA
groups were ventilated (tidal volume 20 ml/kg, respiratory
rate: 50/min, FiO2: 50%, inspiratory:expiratory ratio: 1:1)
for 4 h. Rats in the VA and PVA groups were admin-
istered an intravenous injection of saline or parecoxib
40 mg/kg (Pfizer, Kalamazoo, MI, USA), respectively,
after initiation of large volume ventilation. Rats in the
sham group only received anesthesia. All rats were
sacrificed with an over dose of pentobarbital sodium
for tissue analyses after MV.
Tissue analyses
PaO2 to FiO2 ratio
Arterial blood gases were analyzed using the Bayer Rapidlab
348 analyser (Bayer Diognostics, Germany) to calculate the
ratio of PaO2 to FiO2. Arterial blood gas analyses were
performed at baseline and after MV.
Serum and bronchoalveolar lavage fluid
Peripheral blood was collected and centrifuged at
1500 × g for 10 min. Cytokine levels were analyzed
in serum.
Bronchoalveolar lavage fluid (BALF) was collected by
injecting and withdrawing five aliquots of 50 ml 4 °C sa-
line into the left lung. BALF was centrifuged (1000 × g
for 15 min) and the supernatant was collected. Protein
levels in BALF were detected with the Bradford method.
Macrophages and neutrophils in BALF were counted
using a cell counter chamber.
Prostaglandin E2, tumor necrosis factor-α (TNF-α)
and interleukin (IL)-1β levels in BALF and serum, and
neutrophil elastase levels in BALF, were evaluated with
enzyme linked immunosorbent assay kits (Wuhan Boster
Bio-Engineering Limited Company, Wuhan, Hubei,
China), according to the manufacturers’ instructions, at
baseline and after MV.
Pulmonary alveolocapillary permeability
Pulmonary alveolocapillary permeability was measured
by sampling a portion of the right lung from sacrificed
rats. The wet weight of right lung tissue was recorded
immediately, and the dry weight was recorded after dry-
ing for 48 h at 60 °C. The ratio of wet to dry weight (W/
D) was calculated to estimate the effect of parecoxib on
pulmonary capillary permeability.
Oxidative stress reaction in VILI
To investigate the effect of parecoxib on the oxidative
stress reaction, malondialdehyde (MDA) levels in BALF
and myeloperoxidase (MPO) activity in lung tissue were
detected with MDA and MPO assay kits (Nanjing
Jiancheng Corp., Nanjing, Jiangsu, China).
Lung tissue histopathologic analysis
A portion of the right lung from sacrificed rats was fixed
with 10% formalin and embedded in paraffin. Lung sec-
tions were stained with hematoxylin and eosin. Two pa-
thologists independently evaluated lung injury under
light microscopy based on an assessment of alveolar
congestion, edema, neutrophil infiltration, hemorrhage,
thickness and integrity of the alveoli, and formation of a
hyaline membrane.
TUNEL staining of lung sections
Apoptosis in lung tissue was investigated with ter-
minal deoxynucleotidyl transferase-mediated biotinyl-
ated deoxyuridine triphosphate nick end labeling
(TUNEL) staining using the Apoptosis Assay kit (Roche
Diagnostics GmbH, Science, Mannheim, German). Sections
of right lung tissue from sacrificed rats were digested with
proteinase K, rinsed with phosphate buffered solution, and
incubated in TUNEL reaction mixture for 60 min at 37 °C.
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After quenching the endogenous peroxidase activity with
hydrogen peroxide, sections were placed in extra-avidin
peroxidase and diaminobenzidine solution. Sections were
counterstained with Mayer-hematoxylin and dehydrated.
Brown-stained nuclei were considered positive for
apoptosis. Independently, two pathologists calculated
the apoptosis index.
Western blot analysis
A portion of right lung tissue was homogenized and the
protein was extracted. Total protein concentration was
measured with the Bradford method. Aliquots of protein
homogenate were separated on polyacrylamide gels and
protein was transferred onto polyvinylidene fluoride
membranes. Polyvinylidene fluoride membranes were
blocked with 5% milk, immersed in primary anti-
bodies against COX-2 (ab15191, Abcam Biotechnol-
ogy, Cambridge, United Kingdom), B cell lymphoma/
leukemia-2 (Bcl-2), BcL-2-associated X protein (Bax),
and incubated with horseradish peroxidase-linked sec-
ondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, California, United States of America). Bands
were visualized using enhanced chemiluminescence.
Survival analysis
Eight rats in each group were allowed to recover spon-
taneous breath after large volume ventilation. All the
rats received lidocaine infiltrated locally for pain relief.
Survival for 24 h after VILI was assessed. Moribund ani-
mals were defined as bradycardic, with a heart rate < 40
beats per minute, severely lethargic, and unresponsive to
painful stimulation.
Statistical analysis
All data were analyzed with SPSS software version 11.0
(SPSS, Chicago, Illinois, USA). Sample size was calcu-
lated based on a previous study, which showed that a
sample size of 8 rats in each group was required to de-
tect a 20% increase in PaO2/FiO2 with an alpha of 0.05
and a beta of 20%. Normally distributed data are pre-
sented as means ± standard deviation and were analyzed
using the unpaired t-test. Non-normally distributed
data were analyzed with the nonparametric Friedman
test. A P value of <0.05 was considered statistically
significant [18].
Results
Parecoxib improved gas exchange and pulmonary capillary
permeability in VILI
Compared to the S group, the PaO2/FiO2 ratio was de-
creased after 4 h of MV in the VA and PVA groups (both
P < 0.001) (Fig. 1a), and the ratio of W/D weight and
protein concentration in BALF were dramatically in-
creased (both P < 0.05) (Fig. 1b and c).
Parecoxib inhibited the oxidative stress response in VILI
Compared to the S group, MDA levels and MPO activity
in lung tissue were increased in rats in the VA and PVA
groups (both P < 0.05) (Fig. 2a and b).
Parecoxib inhibited inflammation in VILI
Compared to the S group, TNF-α, IL-1β, and prostaglan-
din E2 levels in serum and BALF were increased in the
VA and PVA groups (P < 0.05). Compared to the VA
group, TNF-α, IL-1β, and prostaglandin E2 levels in
serum (Fig. 3a, b and c) and BALF (Fig. 3d, e and f) were
decreased in the PVA group (P < 0.05).
Compared to the S group, the macrophage ratio,
neutrophil ratio and neutrophil elatase levels in BALF
were increased in the VA and PVA groups (P < 0.05).
Compared to the VA group, the macrophage ratio
(Fig. 4a), neutrophil ratio (Fig. 4b), and neutrophil
elatase levels (Fig. 4c) in BALF were decreased in the
PVA group (P < 0.05).
Compared to the S group, COX-2 and Bax protein
levels in lung tissue were increased in the VA and PVA
groups (P < 0.05) (Fig. 5a). Compared to the VA group,
Bax (Fig. 5b) and COX-2 (Fig. 5d) levels in lung tissue
were decreased, but Bcl-2 protein level (Fig. 5c) was in-
creased, in rats in the PVA group (P < 0.05).
Parecoxib attenuated lung injury in VILI
Light microscopic evaluation of the right lung revealed
normal histology in rats in the S group (Fig. 6a, d). Com-
pared to the S group, severe pathophysiological changes
were seen in the right lungs of rats in the VA (Fig. 6b, e)
and PVA groups (Fig. 6c, f ), including collapse of alveoli,
thickening of alveoli walls, severe diffused edema of al-
veoli and the interstitial space, formation of a hyaline
membrane, infiltration of red blood cells, hemorrhage,
and substantial infiltration of neutrophils and macro-
phages in lung parenchyma. In the PVA group, this
pathophysiology was obviously attenuated.
Parecoxib reduced apoptosis in VILI
Apoptotic epithelial and endothelial cells in lung tissue
were observed in the VA and PVA groups, but not the S
group (Fig. 7a). Compared to the VA group, apoptotic
cells were dramatically decreased in the PVA group
(Fig. 7b, c) (P < 0.05).
Parecoxib improved survival following VILI
Compared to the VA group, survival time in the PVA
group was significantly prolonged (P < 0.001) (Fig. 8).
Discussion
The results of this study show that parecoxib improved
gas exchange function and ameliorated VILI in a rat
ARDS model. Parecoxib reduced histopathogical changes
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of VILI and apoptosis, as well as local and systematic in-
flammation compared to saline-treated mechanically ven-
tilated rats. More important, parecoxib improved long
term outcomes and increased survival after VILI in ARDS.
In VILI, mechanical overstretching of epithelial and
endothelial cells can activate NF-κB and promote the re-
lease of chemoattractant and proinflammatory factors,
which activate pulmonary macrophages and recruit neu-
trophils [19, 20]. Activated macrophages and neutrophils
secrete vast amounts of pro-inflammatory cytokines and
elastase leading to pulmonary endothelial injury, hypox-
emia, and lung edema. Patients in the intensive care unit
with ARDS usually require MV, and these patients are
particularly susceptible to VILI because of lung inflam-
mation. COX-2 is widely expressed in different inflam-
matory cells, pulmonary endothelium and epithelium,
and has been associated with the pathophysiology of
VILI and ARDS [11, 14, 17, 21, 22]. Induction of COX-2
results in an increase in prostaglandin E2 and prostacyc-
lin levels, which play important roles in inflammation in
the lung. Several studies show that inhibition or dis-
ruption of the COX-2 gene attenuates VILI and
ARDS [7, 23, 24]. A recent report demonstrated that
inhibition of COX-2 significantly decreased COX ac-
tivity and attenuated VILI [17]. Although interesting,
the clinical relevance of these findings is limited. A
previous study from our laboratory indicates that inhib-
ition of prostaglandin E2 and the COX-2 pathway by pare-
coxib attenuates acute lung injury induced by meconium
[13]. Parecoxib is widely applied in clinical settings; there-
fore, in current study, we observed the effect of parecoxib
on VILI in ARDS, in which prior lung injury or ARDS was
induced with an intravenous injection of endotoxin.
We analyzed the effect of parecoxib on pulmonary gas
exchange function, pulmonary capillary permeability,
and histology in rats with ARDS after 4 h of MV. An in-
crease in lung permeability induced by VILI can result
in severe hypoxemia and lung edema. In this study, pare-
coxib increased the PaO2/FiO2 ratio, decreased the ratio
of lung W/D weight and the protein content in BALF,
Fig. 1 PaO2/FiO2, ratio of W/D weight in lung tissue, and protein concentration in BALF. Parecoxib significantly upregulated PaO2/FiO2 and decreased
the W/D weight ratio in lung tissue and the total protein level in BALF after MV. *P< 0.05 compared with sham group; #P< 0.05 compared with VA group
( , sham group; , VA group; , PVA group) (n= 8 in each group)
Fig. 2 MDA level in BALF and MPO activity in lung tissue. Parecoxib significantly reduced MDA level in BALF and MPO activity in lung tissue after
MV. *P < 0.05 compared with sham group; #P < 0.05 compared with VA group (n = 8 in each group)
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and attenuated histopathogical changes after MV in rats.
The findings suggested that parecoxib can reduce lung
injury, prevent deterioration of alveolocapillary mem-
brane function, and decrease lung edema in a rat model
of ARDS and VILI.
We speculate that our findings are attributed to the
anti-oxidative and anti-inflammatory properties of pare-
coxib. Results from previous studies have indicated that
an oxidative stress response plays an important role in
VILI [25–27]. During VILI, activated neutrophils release
proinflammatory cytokines and reactive oxygen species,
which directly damage pulmonary endothelial and epi-
thelial cell membranes [28, 29]. In the present study,
parecoxib significantly reduced MDA levels in BALF.
MDA is the end product of lipid peroxidation, and
MDA concentrations in serum are directly proportional
to the severity of tissue damage caused by reactive oxy-
gen species [30, 31]. In addition, parecoxib significantly
decreased MPO activity. MPO plays a pivotal role in the
oxidative stress response. MPO mediates peroxidation of
chloride ions to form hypochlorous acid, which can dir-
ectly damage lung epithelial and endothelial cells. MPO
is also a significant source of tyrosine nitration, which
can evoke protein conformational changes and damage
to cell membranes [32, 33]. Evidence suggests that MPO
promotes oxidation and nitrification during ischemia
and reperfusion [34].
Inflammation plays a key role in VILI [35]. MV with
high pressure or a large tidal volume can increase pul-
monary hyperpermeability and contribute to pulmonary
Fig. 3 TNF-α, IL-1β, IL-8, and prostaglandin E2 levels in serum and BALF a. TNF-α, IL-1β, and prostaglandin E2 levels in serum and BALF were significantly
decreased in rats treated with parecoxib (PVA) compared to saline-treated rats (VA group). *P< 0.05 compared with sham group; #P< 0.05 compared with
VA group. ( , sham group; , VA group; , PVA group) (n= 8 in each group)
Fig. 4 Macrophage and neutrophils, and neutrophil elastase levels in BALF. Parecoxib decreased the infiltration of macrophages and neutrophils
induced by MV, and inhibited the release of elastase. *P < 0.05 compared with sham group; #P < 0.05 compared VA group (n = 8 in each group)
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and systemic inflammation [36]. Furthermore, reactive
oxygen species generated during VILI cause direct
cellular damage, lead to severe local inflammation, and
result in rapid transcription of chemokines and pro-
inflammatory cytokines [37]. In the current study, pare-
coxib decreased levels of TNF-α and IL-1β in BALF and
serum, the level of neutrophil elastase in BALF, and his-
topathogical injury in the lung tissue after MV in rats.
These results suggest that parecoxib inhibited local and
systemic inflammation. Anti-inflammatory effects of
parecoxib may be medicated through the inhibition of
prostaglandin E2. Prostaglandin E2, which is released
from epithelial cells, can modulate immune and inflam-
matory responses [38, 39]. In the present study, prosta-
glandin E2 levels in BALF and serum and COX-2 levels
in lung were significantly decreased by parecoxib after
MV. We speculate that parecoxib ameliorated VILI
through inhibition of COX-2, which attenuated prosta-
glandin E2 production. The anti-inflammatory effect of
parecoxib may also result from an inhibition of neutrophil
Fig. 5 COX-2 protein levels in lung tissues. COX-2 protein level in lung tissues was significantly decreased in rats treated with parecoxib (PVA)
compared to saline-treated rats (VA group). *P < 0.05 compared with sham group; #P < 0.05 compared with VA group. ( , sham group; , VA group;
, PVA group) (n = 8 in each group)
Fig. 6 Histopathological analysis of lung tissue. a, d Sham group. b, e VA group. c, f PVA group. a–c × 200. d–f × 400. Lung tissue in the VA group
showed thickened alveolar walls, edema, decreased alveolar space, and obvious inflammatory cell infiltration and hemorrhage. Parecoxib significantly
decreased the degree of MV-induced histopathological injury (n = 8 in each group)
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motility. In the present study, parecoxib significantly de-
creased the number of neutrophils in BALF after MV.
Furthermore, parecoxib inhibited MPO activity, which is
abundantly expressed in neutrophils, and usually corre-
lates well with neutrophil count [40].
Both inflammation and the oxidative stress response
can result in apoptosis, and apoptosis of endothelia and
epithelia cells play a pivotal role in VILI [25, 41]. In the
current study, we found that apoptosis was significantly
inhibited by parecoxib. This result is in accordance with
findings from previous studies [42, 43]. We detected the
levels of Bax and Bcl-2 proteins to explore the role of
parecoxib in apoptosis. Bax is an important pro-
apoptotic protein [44]. In contrast, Bcl-2 can inhibit Bax
activation and attenuate apoptosis. The Bax/Bcl-2 ratio
is essential for controlling apoptosis. In the current
study, parceoxib decreased the level of Bax protein in
lung tissue, but increased the level of Bcl-2 protein.
These results suggest that parecoxib decreased apoptosis
by moderating the Bax/ Bcl-2 ratio.
Conclusions
The results of this present study indicate that parecoxib
can improve gas exchange function, decrease edema, re-
duce local and systemic inflammation, and ameliorate
histological injury and apoptosis induced by VILI in an
ARDS rat model. These findings suggest parecoxib may
be a novel therapeutic option for ARDS patients under-
going MV.
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